Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT00894439 Completed - Healthy Subjects Clinical Trials

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.

NCT ID: NCT00864487 Completed - Healthy Subjects Clinical Trials

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.

NCT ID: NCT00838461 Completed - Healthy Subjects Clinical Trials

Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016

Start date: March 2009
Phase: Phase 1
Study type: Interventional

This is intended to provide an initial safety assessment of HSD-016 and also to evaluate how the drug is absorbed and eliminated and its effect on the body in healthy subjects.

NCT ID: NCT00834288 Completed - Healthy Subjects Clinical Trials

A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions

Start date: June 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study was to compare the pharmacokinetic profiles at steady-state of the test product, Tramadol HCl Once-A-Day (OAD) 200 mg tablets and the reference product, Tramadol HCl 50 mg (IR) tablets (Ortho-McNeil Ultram®). For this purpose, the extent of absorption of tramadol and formation of O-desmethyltramadol (measures of systemic exposure) after multiple administration of 50 mg 6-hourly at 07:30, 13:30, 19:30 and 01:30 (reference product) and 200 mg 24-hourly at 07:30 (test product), were compared.

NCT ID: NCT00822835 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy subjects.

NCT ID: NCT00822484 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy Japanese male subjects.

NCT ID: NCT00820404 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of BLI-489 in Healthy Subjects

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.

NCT ID: NCT00818129 Completed - Healthy Subjects Clinical Trials

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to investigate the safety and tolerability of single and multiple oral doses of AZD7295 in healthy male Japanese subjects. This will be done by comparing the effect of AZD7295 to placebo. The study will aslo investigate the absorption, distribution and disappearance of AZD7295 in the body.

NCT ID: NCT00814060 Completed - Healthy Subjects Clinical Trials

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.

NCT ID: NCT00795730 Completed - Alzheimer Disease Clinical Trials

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease